iShares Edge MSCI Multifactor Healthcare
Inside Pfizer’s Performance in 3Q17
PFE stock rose ~7.3% in 3Q17 and has risen ~11.3% YTD (year-to-date) as of October 16.
What Pfizer’s Valuation Changes after 2Q17 Tell Us
Analysts estimate that Pfizer (PFE) stock has the potential to return ~5.9% over the next 12 months.
Johnson & Johnson’s Medical Devices Segment in 3Q16
Johnson & Johnson’s (JNJ) Medical Devices segment grew ~1.1% to ~$6.2 billion for 3Q16 compared to 3Q15.